Tetrapyrroles and derivatives
Abcam beta-Amyloid Peptide (1-40) (human), 1MG
MW 4330 Da. beta-Amyloid Peptide (1-40) (human). Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam beta-Amyloid Peptide (42-1) (human), Inactive control, 1MG
MW 4514 Da. beta-Amyloid Peptide (42-1) (human), Inactive control. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam beta-Amyloid Peptide (1-42) (human), 1MG
Beta-amyloid peptide (1-42) (human) is with purity of > 95%. - Reconstitute with PBS at 1 mg/mL
The product is subject to the following: Abcam Restricted Use Statement
Abcam AMD3100 octahydrochloride, C x CR4 antagonist, 50MG
MW 794.5 Da, Purity >99%. Plerixafor (hydrochloride) is a macrocyclic compound that acts as an irreversible antagonist against the binding of CXCR4 with its ligand, SDF-1 (CXCL12). It suppresses infection by HIV with an IC₅₀ value of 1-10 ng/ml with selectivity toward CXCR4-tropic virus. Plerixafor mobilizes hematopoietic stem and progenitor cells for transplant better than G-CSF alone. It also increases T-cell trafficking in the blood and spleen as well as the central nervous system. Plerixafor regulates the growth of primary and metastic breast cancer cells and inhibits dissemination of ovarian carcinoma cells.
The product is subject to the following: Abcam Restricted Use Statement
Abcam E x endin-4 (E x enatide), GLP-1 receptor agonist, 500UG
MW 4187 Da, Purity >95%. Exendin-4 (Exenatide), GLP-1 receptor agonist. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam A 943931 dihydrochloride, H4 receptor antagonist, 10MG
MW 368.3 Da, Purity >99%. Potent and selective H4 receptor antagonist (pKi = 7-8). Shows anti-inflammatory and analgesic effects *in vivo.* Orally active.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Nocodazole, Microtubule inhibitor, 5MG
MW 301.32 Da, Purity >98%. Microtubule inhibitor. Rapidly depolymerises microtubules in vivo and inhibits tubulin polymerisation in vitro. Inhibits mitosis. Also reduces stem cell pluripotency factors Oct 4 and Nanog.
The product is subject to the following: Abcam Restricted Use Statement
Abcam SB 216641 hydrochloride, h5-HT1B antagonist, 10MG
MW 523.03 g/mol, Purity >98%. Selective h5-HT₁B receptor antagonist. 25-fold selectivity over h5-HT₁D. Little or no affinity for a range of other receptor subtypes.
The product is subject to the following: Abcam Restricted Use Statement
Abcam omega-Agato x in IVA, Ca2+ channel blocker (P and Q type), 100UG
MW 5202 Da. omega-Agatoxin IVA, Ca2+ channel blocker (P and Q type). Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam SB 203580, p38 MAPK inhibitor, 10MG
MW 377.4 Da, Purity >99%. SB 203580, p38 MAPK inhibitor. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam UDP-glucose, Highly P2Y14 agonist, 1G
MW 610.27 Da. Highly potent, endogenous P2Y14 agonist (EC50 = 82 nM). Involved in modulation of gastric function. UDP also available (ab120383).
The product is subject to the following: Abcam Restricted Use Statement
Abcam x anomeline o x alate, M1 muscarinic acetylcholine receptor agonist, 50MG
MW 371.5 Da, Purity >99%. Functionally preferring M₁ muscarinic acetylcholine receptor agonist (pKi values are 7.1 (M₁), 6.9 (M₂), 7.4 (M₃), 7.7 (M₄) and 7.4 (M₅)). Able to cross blood-brain barrier. Displays antipsychotic activity.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Desmethyl YM298198 hydrochloride, Analogue of mGlu1 antagonist YM298198, 10MG
MW 364.9 Da, Purity >99%. Derivative of mGlu1 antagonist YM298198 (ab120015). Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Necrostatin-1, necroptosis inhibitor, 50MG
MW 259.33 Da, Purity >99%. Potent, specific necroptosis inhibitor (EC₅₀ = 490 nM). Selective allosteric inhibitor of death domain receptor-associated adaptor kinase RIP1 in vitro (EC₅₀ = 182 nM). Caspase independent, programmed necrosis pathway.
The product is subject to the following: Abcam Restricted Use Statement
Abcam SB 243213 dihydrochloride, 5HT2C receptor antagonist, 50MG
MW 464.9 Da, Purity >99%. Potent, selective 5-HT2C receptor antagonist (Ki = 1 nM). Neurological agent. Active *in vivo* and *in vitro*.
The product is subject to the following: Abcam Restricted Use Statement